Intellectual Property

CardioVax owns and maintains an intellectual property portfolio that protects CardioVax's candidate products as well as the novel therapeutic target the therapies use to modulate the immune system – apoB–100 (a component of LDL).

 

In addition, our intellectual property also covers several medical uses of our therapies for treating conditions related to atherosclerosis and for companion diagnostics to gauge the efficacy of the drug. Cardiovax has 60 issued patents in the United States, Europe, Australia, Russia, China, Japan, and India. Additional patents are pending in multiple countries in the Americas, Europe, and Asia.

 

Issued US patents include:

 

  • US 7,527,795
  • US 7,528,225
  • US 7,544,360
  • US 7,556,811

 

NEXT> Publications

CV Logo Footer

10100 Santa Monica Blvd., Suite 925

Los Angeles, CA 90067 United States

Tel.: 424. 263. 6364

pagend